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Abstract The placenta contains a large variety of meta-
bolizing enzymes, among them UDP-glucuronosyltransfer-
ase (UGT). Several UGT2B isozymes have so far been
detected in human placenta, but little is known on placental
expression of UGT1A isozymes. The antiepileptic drug
lamotrigine (LTG) is a UGT1A4-substrate, and its serum
concentration falls by over 50% during pregnancy, leading
to impaired seizure control. The placenta may be involved
in this. Microsomes from term placentas of 4 LTG-users
and 10 healthy control subjects were prepared. Western
blot analysis detected UGT1A proteins in all placentas. The
presence of UGT1A4 in placenta from LTG users was
conﬁrmed with UGT1A4 commercial standard and a spe-
ciﬁc UGT1A4 primary antibody. Since LTG is primarily
metabolized by UGT1A4 and this isozyme is shown to be
present in placenta at term, it may be hypothesized that the
placenta is involved in the fall of LTG serum concentra-
tions during pregnancy.
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1 Introduction
UDP-glucuronosyltransferases (UGTs) are a mammalian
superfamily of phase II metabolizing enzymes, of which
UGT1A and UGT2B are the most important subfamilies.
To date, 25 UGT1A and UGT2B isozymes have been
identiﬁed in humans (Mackenzie et al. 2005). UGTs cata-
lyze the binding of glucuronic acid to endo- and exogenous
compounds, e.g., hormones or drugs. This is an important
process that increases their solubility in water and aids in
their urinary excretion. UGTs have been found in a variety
of organs and tissues, including liver, lungs, intestinal
mucosa, brain, uterus and placenta, in both animals and
humans (Mackenzie et al. 2005; Myllynen et al. 2005,
2007; Nakamura et al. 2008; Syme et al. 2004).
UGT activity is regulated by various pre- and posttrans-
lational mechanisms, e.g., hormones, liver-enriched tran-
scription factors, ligand-activated transcription factors, and
the aryl hydrocarbon receptor (Bock 2010; Ishii et al. 2010).
These ﬁndings relate mostly to experiments with hepatic
UGT. Very little is known on the extent and intrinsic regu-
lation of human placental UGT activity. External factors,
e.g., enzyme-inducing drugs, ethinyl estradiol or cigarette
smoke may increase UGT activity. Some UGT1A4-sub-
strates, e.g., the antiepileptic drug lamotrigine (LTG), may
even induce their own metabolism to a certain degree
(Hussein and Posner 1997; May et al. 1996; Ohman et al.
2008; Reimers et al. 2005; Villard et al. 1998).
LTG serum concentrations fall by over 50% during
pregnancy, most presumably due to increased glucuroni-
dation (de Haan et al. 2004; Ohman et al. 2008, 2000;
Pennell et al. 2004; Petrenaite et al. 2005). This may lead to
loss of seizure control and the necessity to increase the
LTG dose (Petrenaite et al. 2005). It is unlikely that
pregnancy-induced hemodilution plays a major role in this
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10–15% (Klajnbard et al. 2010). Moreover, it has been
shown that increased glucuronidation of LTG is the most
probable mechanism (Ohman et al. 2008). It is reasonable
to assume that most of this glucuronidation takes place in
the liver. However, UGT has been found in many other
tissues also, including the placenta. The placenta is a major
detoxifying organ, protecting the fetus from potentially
harmful compounds by means of various enzymes and
transporters (Myllynen et al. 2005, 2007; Syme et al.
2004). In contrast to the placental expression of cyto-
chrome P450 enzymes, data on placental UGT expression
is scarce. So far, few different isozymes of the UGT2B-
family have been detected in placental tissue. UGT1A
protein expression was found in ﬁrst trimester human
placenta, but not in placenta at term (Collier et al. 2002a,
b). Unfortunately, these studies did not distinguish between
the different UGT1A isozymes. A more recent study found
DNA-transcripts of UGT1A6, but no other UGT1A iso-
zyme, in placental tissue (Zhang et al. 2007).
Since it is unknown where in the body the increased
glucuronidation of LTG takes place, and which role the
placenta plays in this context, we wished to investigate
whether UGT1A4 is expressed in human placenta.
2 Methods
2.1 Placenta specimens and preparation of microsomes
Placentas from 10 healthy, non-smoking, normal-term
pregnant women (controls; samples 1–10) and four non-
smoking, normal-term pregnant women using LTG without
enzyme-inducing co-medication (LTG-users; samples
11–14) were taken immediately after cesarean section or
vaginal delivery and microsomes of the villous part were
prepared within 30 min. Microsomes were prepared by
calcium precipitation according to Kamath and Rubin
(1972). Brieﬂy, villous tissue from the placenta was
homogenized in 0.25 M icecold sucrose and the homoge-
nate was centrifuged at 12,000g for 20 min to obtain a
postmitochondrial supernatant (PMS). The PMS was sub-
jected to microsomal aggregation by addition of Ca
2? and
then centrifuged again at 27,000g for 15 min. The micro-
somal pellets obtained were suspended in 0.1 M Tris buffer
(pH 7.4), added glycerol (ﬁnal glycerol concentration was
15%) and stored at -80C until use. Preparation of
microsomes was performed at 4C. The protein concen-
trations were determined using the Bradford protein assay
(Bio-Rad Laboratories), with bovine serum albumin as the
protein standard (Bradford 1976).
All study subjects gave their written informed consent.
The study was approved by the regional ethics committee.
2.2 Western blotting
SDS polyacrylamide gel electrophoresis (SDS–PAGE) was
performed according to the method of Laemmli (1970),
with minor modiﬁcations. Western blot analysis was per-
formed basically according to Towbin et al. (1979). Pla-
cental microsomal proteins were denaturated by boiling for
4 min in sample treatment buffer (0.125 M Tris–HCl, pH
6.8, 20% glycerol, 4% sodium dodecyl sulfate, 0.004%
bromophenol blue, and 10% 2-mercaptoethanol). Placental
microsomal proteins were loaded (30 lg per lane) and
separated using 4–20% linear gradient gel in Tris–HCl
(Bio-Rad Laboratories) for approximately 50 min at
200 V. Human UGT1A4 supersomes (BD Gentest) were
treated in sample treatment buffer analogous to the pla-
cental microsomes and then loaded as standard. In addition,
human UGT1A1 microsomes (BD Gentest) were loaded as
standard. The resolved proteins were transferred electro-
phoretically to a 0.45-lm nitrocellulose membrane (Bio-
Rad Laboratories) at 100 V for 1 h. The nitrocellulose
sheets were blocked overnight by treatment with 5% skim
milk in Tris-buffered saline (TBS) containing 0.1%
Tween20. The membranes were rinsed and treated for 1 h
with a 1:1,000 dilution of WB-UGT1A primary antiserum
(BD Gentest) or a 1:500 dilution of a speciﬁc UGT1A4
primary antiserum (Santa Cruz Biotechnology). The
membranes were rinsed four times for 10 min and incu-
bated for 1 h with a 1:1,000 dilution of horse radish per-
oxidase (HRP) conjugated goat anti-rabbit IgG (BD
Gentest) or a 1:5,000 dilution of HRP conjugated donkey
anti-goat IgG (Santa Cruz Biotechnology), respectively.
Membranes were washed four times with TBS and
visualized using Western Lightning Chemiluminescence
reagents according to the manufacturer’s instructions (BD
Gentest and Santa Cruz Biotechnology) followed by light
detection on luminescence detection ﬁlm (Amersham
Bioscience).
3 Results and discussion
UGT1A proteins were detected, using WB-UGT1A pri-
mary antibody, in all four placental samples from women
using LTG (Fig. 1a). Two bands were detected in every
sample, and one of them co-migrated with the UGT1A4
standard. Western blot analyses with UGT1A4 primary
antibody also illustrated the presence of bands, further
indicating the presence of the UGT1A4 isozyme (Fig. 1b).
The other band detected by WB-UGT1A (Fig. 1a) corre-
sponded to neither the UGT1A4 nor the UGT1A1 standard,
which indicates the presence of another isoform of UGT1A
in the placenta samples. The WB-UGT1A primary anti-
body used in this study detects several isoforms of human
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(mobility range 52–58 kDa)). In a previous study, DNA-
transcripts of UGT1A6, but not UGT1A1, UGT1A3,
UGT1A4, UGT1A5, UGT1A7, UGT1A8, UGT1A9, and
UGT1A10, have been found in human placenta (Zhang
et al. 2007). Thus, the unidentiﬁed band may be caused by
UGT1A6. The fact that this latter study did not ﬁnd evi-
dence for placental expression of UGT1A4 may be due to
considerable methodological differences (DNA-transcripts
vs. UGT1A4 protein itself) and the use of a different kind
of placental tissue preparation.
UGT1A proteins were also detected in placental samples
from the 10 control women not using LTG. A representa-
tive immunoblot of microsomes from control women
(showing samples 1–7) and UGT1A4 standard is shown in
Fig. 2. Although equal amounts of total placental protein
and UGT1A4 standard were used in the different immu-
noblots, weaker bands of UGT1A were detected in the
placentas of the control group (Fig. 2), compared to the
LTG-user group (Fig. 1). However, our experiments,
which were designed to detect UGT1A and UGT1A4
qualitatively, were not suited for quantitative measure-
ments. Moreover, only four placentas were available from
LTG-users. Thus, the observed differences in band inten-
sity do not prove real quantitative differences in UGT1A4
expression. It has, though, previously been found that LTG
induces its own metabolism (Hussein and Posner 1997).
Therefore, it may be hypothesized that LTG-users express
higher levels of UGT1A4 than controls due to enzyme
induction. Quantitative studies are needed to prove this
theory.
UGT1A4 mRNA has previously been found in human
liver, stomach, small intestine, colon, kidney, bladder,
trachea and ovary, but not in brain, lung, adrenal gland,
breast, uterus and testis (Kaivosaari et al. 2007, Nakamura
et al. 2008). To our knowledge, our study is the ﬁrst one to
demonstrate UGT1A4 protein in human term placenta.
This ﬁnding suggests that placental UGT1A4 activity may
contribute to the signiﬁcant fall of LTG serum concentra-
tions during pregnancy. Further studies, e.g., quantitative
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Fig. 1 UGT1A (a) and
UGT1A4 (b) protein expression
in term placenta from women
using lamotrigine. Microsomal
proteins were isolated from
placental tissue and analyzed by
Western blotting with
antibodies for the UGT1A
protein subfamily (a)o r
UGT1A4 isozyme (b).
11–14 = microsome samples
from four subjects. Equal
amounts (30 lg) of microsomal
total protein were loaded for
each lane. Human UGT1A4
supersomes and human
UGT1A1 microsomes were
used as standards (a). The
patterns shown are
representative for a series of two
or three replicate blots
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Fig. 2 UGT1A protein expression in term placenta from healthy
subjects. Microsomal proteins were isolated from placental tissue and
analyzed by Western blotting with a speciﬁc antibody for the UGT1A
protein subfamily. 1–7 = microsome samples from seven subjects.
Equal amounts (30 lg) of microsomal total protein were loaded for
each lane. Human UGT1A4 supersomes were used as standards. The
pattern shown is representative for a series of two or three replicate
blots
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tissue or whole perfused placentas are necessary to conﬁrm
our ﬁndings and to evaluate this hypothesis.
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